Ajanta Pharma

Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period

Dr Ramesh Jhawar, President of Ajanta Pharma, and a veteran with over four and half decades of experience in the life sciences…

Company posted profit after tax at Rs. 95 crores

Zolmitriptan tablets are part of an 'ever-growing portfolio' that the company has developed for the US market Ajanta Pharma has…

Revenue from operations grew 14 per cent at Rs 426 crores against Rs 372 crores in Q4 FY 2016

Ajanta Pharma USA is scheduled to launch the almotriptan malate tablets in the US shortly Ajanta Pharma has received final…

Net sales of the company rose to Rs 465.71 crore for the December quarter Ajanta Pharma has reported a 19.60 per cent increase in…

US FDA has approved montelukast offerings in three dosage forms viz immediate-release tablets, chewable tablets, and oral granules…

EBITDA growth was at Rs 154 crore Ajanta Pharma has reported its performance for the second quarter and half year ended September…

The company has been ranked as the third largest wealth creator Ajanta Pharma has been ranked as the third largest wealth creator…